Plerixafor
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Plerixafor: From Stem Cell Mobilization to Indolent Plasma Cell Myeloma
One-Sentence Summary
Plerixafor is a CXCR4 antagonist originally used to mobilize peripheral blood stem cells for autologous transplantation in patients with lymphoma and multiple myeloma. The TxGNN model predicts it may be effective for Indolent Plasma Cell Myeloma, but currently 0 clinical trials and 0 publications directly support this specific indication — the signal rests entirely on mechanistic reasoning.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Peripheral blood stem cell mobilization prior to autologous transplantation (non-Hodgkin lymphoma, multiple myeloma) |
| Predicted New Indication | Indolent Plasma Cell Myeloma |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L4 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Plerixafor is a CXCR4 chemokine receptor antagonist that is well established as an adjunct to G-CSF for mobilizing hematopoietic stem cells in patients with non-Hodgkin lymphoma and multiple myeloma prior to autologous transplantation (confirmed by trial documentation in the evidence pack, e.g. NCT01319864: “Plerixafor is FDA approved for mobilizing stem cells from the bone marrow”).
Mechanistically, the CXCR4/CXCL12 axis also governs the homing and survival of malignant plasma cells within the bone marrow niche. Because plerixafor already has extensive safety experience in myeloma patients (in the stem-cell-mobilization setting), the hypothesis that blocking this same axis could reduce plasma cell tumor burden in indolent plasma cell myeloma is biologically plausible.
That said, this remains a theoretical extrapolation. No trial or publication in this evidence pack tests plerixafor as a direct treatment for indolent/smoldering myeloma — the rationale is built entirely on the drug’s known pharmacology and its established, but indirect, safety footprint in the myeloma population.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Plerixafor currently holds no marketing authorization in this registry (status: Not Marketed, 0 authorizations recorded). No product, dosage form, or approved-indication data is available to tabulate.
Safety Considerations
Please refer to the SmPC for safety information.
Note: Both key warnings and contraindications are flagged as a Blocking data gap (DG001) in the evidence pack — TFDA/label-level safety data has not yet been retrieved, which by itself prevents this candidate from clearing initial safety screening (S1).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (indolent plasma cell myeloma) has no direct clinical trial or literature support — evidence level L4 reflects mechanism-only reasoning. Combined with a blocking data gap on warnings/contraindications and the drug’s current unmarketed status in this jurisdiction, there is not enough evidence to move this specific indication past a research hypothesis.
To proceed, the following is needed:
- Resolve DG001 (Blocking): retrieve label-level warnings and contraindications before any S1 safety evaluation
- Resolve DG002: obtain confirmed mechanism-of-action detail from DrugBank/SmPC
- Generate or identify preclinical/clinical data testing plerixafor specifically in indolent/smoldering plasma cell myeloma (current evidence only covers active myeloma stem-cell mobilization, not indolent-stage treatment)
- Consider that among the 10 candidates in this evidence pack, myeloid leukemia (rank 7) has substantially stronger support — evidence level L2, with multiple completed Phase 1/2 trials (e.g. NCT01352650, NCT00990054, PMID 22308295, PMID 29724902) testing plerixafor as a CXCR4-blocking chemosensitizer. If the sponsor wants to advance a plerixafor repurposing program, that indication warrants separate, prioritized evaluation ahead of indolent plasma cell myeloma.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.